Status:
UNKNOWN
Respiratory Side Effects of Busulfan High Dose Chemotherapy in a Pediatric Population
Lead Sponsor:
University Hospital, Strasbourg, France
Conditions:
Signs and Symptoms, Respiratory
Eligibility:
All Genders
3-18 years
Phase:
PHASE2
Brief Summary
Recently, several conditioning regimens did not include total body irradiation (TBI) anymore, especially in the case of young children due to cognitive sequelae and late effects on growth and height. ...
Eligibility Criteria
Inclusion
- Inclusion Criteria:
- Patients above 3 years old treated by busulfan or TBI in their conditioning regimens before allograft or busulfan in high dose chemotherapeutic regimens followed by autograft will be included after parents informed assent.
Exclusion
Key Trial Info
Start Date :
July 1 2006
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
June 1 2012
Estimated Enrollment :
35 Patients enrolled
Trial Details
Trial ID
NCT00328029
Start Date
July 1 2006
End Date
June 1 2012
Last Update
February 25 2009
Active Locations (2)
Enter a location and click search to find clinical trials sorted by distance.
1
Service d'Explorations Fonctionelles Respiratoires - Hôpital Civil
Strasbourg, France, 67091
2
Service de Pédiatrie Onco-Hématologie - Hôpital de Hautepierre
Strasbourg, France, 67098